Virus therapy joins chemo to fight rectal cancer

NCT ID NCT06459869

Recruiting now Disease control Sponsor: Akamis Bio Source: ClinicalTrials.gov ↗

First seen Dec 29, 2025 · Last updated Apr 23, 2026 · Updated 22 times

Summary

This trial tests a new treatment called NG-350A, a virus that targets tumor cells and boosts the immune system, combined with standard chemoradiotherapy. It is for adults with locally advanced rectal cancer who have a high risk of the cancer coming back. The goal is to see if this combination can shrink or eliminate the tumor before surgery.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

AdventHealth Orlando
RECRUITING

Orlando, Florida, 32804, United States

Contact
Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States

Contact
The Royal Marsden NHS Foundation Trust
RECRUITING

Sutton, United Kingdom

Contact
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

Contact
University College London NHS FT
RECRUITING

London, United Kingdom

Contact
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

Contact

Conditions

Explore the condition pages connected to this study.

LOCALLY ADVANCED RECTAL CANCER (LARC)